André R Brunoni1, Frank Padberg2, Erica Leandro Marciano Vieira3, Antônio Lucio Teixeira4, André F Carvalho5, Paulo Andrade Lotufo6, Wagner F Gattaz7, Isabela Martins Benseñor6. 1. University Hospital, University of São Paulo, São Paulo, Brazil; Service of Interdisciplinary Neuromodulation (SIN), Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil; Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry (INBioN), Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.; Department of Psychiatry and Psychotherapy, University Hospital, LMU, Munich, Germany. Electronic address: brunoni@usp.br. 2. Department of Psychiatry and Psychotherapy, University Hospital, LMU, Munich, Germany. 3. Interdisciplinary Laboratory of Medical Investigation, Federal University of Minas Gerais, Minas Gerais, Brazil. 4. Interdisciplinary Laboratory of Medical Investigation, Federal University of Minas Gerais, Minas Gerais, Brazil; Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, TX, USA. 5. Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, ON, Canada,; Center for Addiction and Mental Health (CAMH), Toronto, ON M6J 1H4, Canada. 6. University Hospital, University of São Paulo, São Paulo, Brazil. 7. Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry (INBioN), Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.
Abstract
BACKGROUND:Transcranial direct current stimulation (tDCS) holds promise as a therapeutic intervention for major depressive disorder (MDD). A more precise understanding of its underlying mechanisms may aid in the identification of subsets of patients responsive to tDCS within the context of precision psychiatry. OBJECTIVE: In this ancillary investigation of the Escitalopram vs. Electrical Current Therapy for Treating Depression Clinical Study (ELECT-TDCS), we investigated whether plasma levels of several cytokines and neurotrophic factors associated with major depression or antidepressant response predicted tDCS effects. METHODS: We examined, in 236 patients at 3 timepoints during a 10-week treatment course, plasma levels of nerve growth factor (NGF), brain-derived (BDNF), glial-cell line derived neurotrophic factor (GDNF), the interleukins (IL) IL-1ß, IL-6, IL-8, IL-10, IL-12p70, IL-18, IL-33, tumor necrosis factor-alpha (TNF-alpha), and its soluble receptors sTNFr1 and sTNFr2. General linear models and mixed-models analyses of variance were used to respectively assess whether plasma levels of these molecules (1) predicted tDCS antidepressant improvement and (2) changed over time. RESULTS: After correction for multiple comparisons (false discovery rate method), NGF baseline levels predicted early depression improvement for tDCS vs. escitalopram, whilst other biomarkers did not significantly predict treatment improvement. The levels of IL12p70, IL10, IL-1ß, IL-8 and sTNFr1 decreased over time, regardless of allocation group and clinical response. CONCLUSION: In general, peripheral biomarkers were not associated with the outcome. The post-hoc finding of baseline NGF levels predicting early depression improvement for tDCS should be explored in further studies.
RCT Entities:
BACKGROUND: Transcranial direct current stimulation (tDCS) holds promise as a therapeutic intervention for major depressive disorder (MDD). A more precise understanding of its underlying mechanisms may aid in the identification of subsets of patients responsive to tDCS within the context of precision psychiatry. OBJECTIVE: In this ancillary investigation of the Escitalopram vs. Electrical Current Therapy for Treating Depression Clinical Study (ELECT-TDCS), we investigated whether plasma levels of several cytokines and neurotrophic factors associated with major depression or antidepressant response predicted tDCS effects. METHODS: We examined, in 236 patients at 3 timepoints during a 10-week treatment course, plasma levels of nerve growth factor (NGF), brain-derived (BDNF), glial-cell line derived neurotrophic factor (GDNF), the interleukins (IL) IL-1ß, IL-6, IL-8, IL-10, IL-12p70, IL-18, IL-33, tumor necrosis factor-alpha (TNF-alpha), and its soluble receptors sTNFr1 and sTNFr2. General linear models and mixed-models analyses of variance were used to respectively assess whether plasma levels of these molecules (1) predicted tDCS antidepressant improvement and (2) changed over time. RESULTS: After correction for multiple comparisons (false discovery rate method), NGF baseline levels predicted early depression improvement for tDCS vs. escitalopram, whilst other biomarkers did not significantly predict treatment improvement. The levels of IL12p70, IL10, IL-1ß, IL-8 and sTNFr1 decreased over time, regardless of allocation group and clinical response. CONCLUSION: In general, peripheral biomarkers were not associated with the outcome. The post-hoc finding of baseline NGF levels predicting early depression improvement for tDCS should be explored in further studies.
Authors: Andre R Brunoni; Angel Carracedo; Olalla M Amigo; Ana L Pellicer; Leda Talib; Andre F Carvalho; Paulo A Lotufo; Isabela M Benseñor; Wagner Gattaz; Carolina Cappi Journal: Braz J Psychiatry Date: 2019-11-11 Impact factor: 2.697
Authors: Gianluca Pandolfo; Giovanni Genovese; Marco Casciaro; Maria Rosaria Anna Muscatello; Antonio Bruno; Giovanni Pioggia; Sebastiano Gangemi Journal: Medicina (Kaunas) Date: 2021-03-26 Impact factor: 2.430
Authors: Lucas Borrione; Helena Bellini; Lais Boralli Razza; Ana G Avila; Chris Baeken; Anna-Katharine Brem; Geraldo Busatto; Andre F Carvalho; Adam Chekroud; Zafiris J Daskalakis; Zhi-De Deng; Jonathan Downar; Wagner Gattaz; Colleen Loo; Paulo A Lotufo; Maria da Graça M Martin; Shawn M McClintock; Jacinta O'Shea; Frank Padberg; Ives C Passos; Giovanni A Salum; Marie-Anne Vanderhasselt; Renerio Fraguas; Isabela Benseñor; Leandro Valiengo; Andre R Brunoni Journal: Braz J Psychiatry Date: 2020-03-16 Impact factor: 2.697
Authors: Klaus Lieb; Nadine Dreimüller; Stefanie Wagner; Konrad Schlicht; Tanja Falter; Alexandra Neyazi; Linda Müller-Engling; Stefan Bleich; André Tadić; Helge Frieling Journal: Front Psychiatry Date: 2018-10-26 Impact factor: 4.157